
TSE:CLS
Pitfalls would include chasing or buying too much. Other risks are not following it and not having a plan. Acceleration is really strong. Good volume along with the buying, which is supportive. Reaching a bit of a limit right now, which may be profit taking, and may pull back to $110. A drop below $105 with a full position is a problem.
It has changed a lot and starting to focus more on helping clients develop new projects. It is riding the AI boom and has just passed the old high from23 years ago. Has had a very low multiple for a long time. It has started to execute better, grow faster and meet expectations. It is quite cheap in terms of tech stocks and should do quite well from a momentum standpoint.
Keeps going up. Business has totally morphed into value-added parts in the semiconductor space. Riding the wave of massive growth of all chipmakers. Valuation seems reasonable. Remember that semis are cyclical; ASML, for example, went down 20% yesterday. Hot stocks always have potential to re-rate.
Quite well run, but not ready to be there. His preference is TSM, but its valuation is not attractive either.
Trending higher above the 200-day MA, which itself is moving higher. Watch it in terms of how far the valuation goes. Right now, 15x forward earnings with about a 13% growth rate for 2025, 29% for 2026. Valuation is actually not as expensive as a lot of other tech names, especially in the US. Valuation and technicals look decent.
12-month price target of $79, still a bit of room. On the chart, you can see the highs that go back to the early summer. Buy 1/3 here around $68, another at just under $64 where there seems to be some support, and the final 1/3 at just over $60. Put in a stop around $54-55.
Concentration risk, but its manufacturing and platform solutions are state of the art. Client base includes hyperscalers and service providers. Extremely well run.
Pulled back in July, rallied to a lower high, now has pulled back to just above the rising 200-day MA. Price pattern is a lot like big tech. Hold, but don't add. If you own it, use the 200-day as a line in the sand. Watch those lows from July. Be cautious. If it breaks $60, need to have a hard discussion.
Solid fundamentals. Healthcare solutions will pay dividends going forward. Not a bad valuation for a long-term play over the next 5 years.